This website uses cookies. By using the site you are agreeing to our Privacy Policy.



Fujifilm announces Launch of FUJIFILM Toyama Chemical

A company for research, development, manufacture and sale of diagnostic and therapeutic drugs

October 1, 2018

FUJIFILM Corporation (President: Kenji Sukeno) announces the launch of FUJIFILM Toyama Chemical Co., Ltd (President: Junji Okada) on October 1, 2018. The company will engage in the research, development, manufacture and sale of diagnostic and therapeutic drugs.

FUJIFILM Toyama Chemical was formed through the merger of TOYAMA CHEMICAL CO., LTD. (Toyama Chemical), a company engaged in the research, development, manufacture and sale of small molecule pharmaceuticals and FUJIFILM RI Pharma Co., Ltd., a company engaged in the research, development, manufacture and sale of radiopharmaceuticals in order to accelerate the development of diagnostic and therapeutic drugs.

Together with FUJIFILM Corporation, engaging in activities including new drug research, FUJIFILM Toyama Chemical will seek to develop new diagnostic and therapeutic radiopharmaceuticals and other new pharmaceuticals with unique mechanisms of action to address areas of significant unmet medical needs in the fields of oncology, central nervous system disorders and infectious diseases. In addition, FUJIFILM Toyama Chemical will also strive to develop new drugs that harness “drug delivery systems” designed to precisely deliver the required dose of pharmaceuticals to designated areas of the body at the necessary time. The company will leverage the in vitro diagnostic devices and reagents owned by FUJIFILM Corporation in addition to diagnostics drugs in order to expand its product portfolio to provide total solutions for patients at all stages from diagnosis through to treatment.

Pharmaceuticals for which Toyama Chemical had acquired manufacturing and marketing approval and held sales rights are currently being sold by Taisho Toyama Pharmaceutical Co., Ltd., but from April 1, 2019 onwards, these products will be sold by FUJIFILM Toyama Chemical. However, the antibiotic combination product consisting of semisynthetic antibiotic and β-lactamase inhibitor Zosyn, jointly developed together with Taiho Pharmaceutical Co., Ltd., will be sold by Taiho Pharmaceutical Co., Ltd. which has the license of manufacturing and distribution from April 1 2019 onwards.

Through its engagement in the pharmaceuticals business, principally through the business activities of FUJIFILM Toyama Chemical, Fujifilm is committed to expanding its business through the creation of innovative pharmaceuticals, while also contributing to resolve various issues facing society.

Overview of FUJIFILM Toyama Chemical Co., Ltd.
Company Name FUJIFILM Toyama Chemical Co.,Ltd.
Address 14-1, Kyobashi 2-Chome, Chuo-ku, Tokyo Japan
Capital 490 million yen (100% owned by FUJIFILM Corporation)
Main Business Activities Research, development, manufacture, sale, export, and import of pharmaceuticals (diagnostic and therapeutic agents) and related devices
Directors Director and Chairperson           Kenji Sukeno
Representative Director and President,
Corporate Vice President              Junji Okada
Director and Senior Executive Vice President   Yoshimitsu Ando
Director and Senior Executive Vice President  Shunichiro Ishikawa
Director and Executive Vice President       Kozo Kobayashi
Outside Director                 Takatoshi Ishikawa
Outside Director                Toshikazu Ban
Auditor                    Akira Fujisawa
Outside Auditor                Tetsuo Imada
Corporate Vice President           Hiroyuki Kasahara
Corporate Vice President           Ryosuke Yamada
Corporate Vice President            Takahiro Sanzen
Corporate Vice President           Takao Yamamoto
Corporate Vice President           Toshiya Morita

For inquiries on information in this media release, contact:

Media Contact:
Corporate Communications Division
TEL :+81-3-6271-2000
Other:
Pharmaceutical Products Division
TEL :+81 3-6271-2171